von Bernstorﬀ W, Voss M, Freichel S, Schmid A, Vogel I, Jöhnk C , et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin CancerRes. (2001)7:925s −32s. 87. Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simo n I, et al. Control of T-cell–mediated immune response by HLA class I in human pancreaticcarcinoma. ClinCancerRes. (2005)11:498–504. 88. BracciL,SchiavoniG,SistiguA,BelardelliF.Immune-basedmech anismsof cytotoxic chemotherapy: implications for the design of novel and ra tionale- based combined treatments against cancer. Cell Death Diﬀer. (2014) 21:15– 25.doi:10.1038/cdd.2013.67 89. Burris,HAIII,MooreMJ,AndersenJ,GreenMR,RothenbergML, Modiano MR,etal.Improvementsinsurvivalandclinicalbeneﬁtwithgemcita bineas ﬁrst-line therapy for patients with advanced pancreas cancer: a ran domized trial.JClinOncol. (1997)15:2403–13.doi:10.1200/JCO.1997.15.6.2403 90. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patien ts undergoing curative-intent resection of pancreatic cancer: a ra ndomized controlledtrial. JAMA.(2007)297:267–77.doi:10.1001/jama.297.3.267 91. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Eﬀect of gemcita bine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer ImmunolImmunother.